GATA3 and breast carcinoma: Heterozygous mutations in GATA3, mostly frameshifts, occur in approximately 15% of primary ER+ human breast cancers, suggesting that Gata3 may function as a haploinsufficient tumor suppressor for luminal breast cancers.